DaVita Inc. (DVA) Debt to Equity Ratio: -23.12
Is DaVita Inc.’s debt to equity ratio high or low?
DaVita Inc.'s debt to equity ratio of -23.12 is 189% below its 5-year average of 25.99, near the low end of its 5-year range (-23.12–99.63).
As of Monday, June 15, 2026. 141.98% below its 12-month average of 55.08.
DVA Debt to Equity Ratio Chart
DVA Average Debt to Equity Ratio Chart
DVA Current vs Average Debt to Equity Ratio Chart
DVA Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
-23.12
DEBT TO EQUITY RATIO AVG TTM
55.08
DEBT TO EQUITY RATIO AVG 3Y
35.65
DEBT TO EQUITY RATIO AVG 5Y
25.99
DEBT TO EQUITY RATIO AVG 10Y
15.10
DEBT TO EQUITY RATIO AVG 15Y
5.11
DEBT TO EQUITY RATIO AVG 20Y
2.84
CURRENT VS TTM AVG
-141.98%
CURRENT VS 3Y AVG
-164.85%
CURRENT VS 5Y AVG
-188.96%
CURRENT VS 10Y AVG
-253.08%
CURRENT VS 15Y AVG
-552.27%
CURRENT VS 20Y AVG
-914.42%
DVA Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DaVita Inc. (DVA) | $13.40B | -23.12 | 55.08 | 35.65 | 25.99 |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 0.34 | 0.33 | 0.35 | 0.36 |
| Solventum Corporation (SOLV)vs › | $13.66B | 1.00 | 1.85 | 1.10 | 0.74 |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 0.03 | 0.03 | 0.03 | 0.03 |
| Baxter International Inc. (BAX)vs › | $10.77B | 1.63 | 1.78 | 2.05 | 1.83 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 3.23 | 2.45 | 1.88 | 1.68 |
| Hologic, Inc. (HOLX)vs › | $16.97B | 0.52 | 0.52 | 0.55 | 0.69 |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | 0.97 | 0.88 | 0.91 | 0.99 |
| Tempus AI, Inc. (TEM)vs › | $8.35B | 1.66 | 4.99 | 4.99 | 4.99 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 0.21 | 0.21 | 0.18 | 0.13 |
Financial Health
Debt/Equity
-23.12
Current Ratio
1.29
DaVita Inc. Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DaVita Inc. Debt to Equity Ratio FAQ
- What is the debt to equity ratio for DaVita Inc. (DVA)?
- The debt to equity ratio for DVA stock is -23.12.
- Is DaVita Inc.'s debt to equity ratio high or low?
- DaVita Inc.'s debt to equity ratio of -23.12 is 189% below its 5-year average of 25.99, near the low end of its 5-year range (-23.12–99.63).
- What is the TTM average debt to equity ratio for DaVita Inc. (DVA)?
- The TTM average debt to equity ratio for DVA stock is 55.08.
- What is the 3Y average debt to equity ratio for DaVita Inc. (DVA)?
- The 3Y average debt to equity ratio for DVA stock is 35.65.
- What is the 5Y average debt to equity ratio for DaVita Inc. (DVA)?
- The 5Y average debt to equity ratio for DVA stock is 25.99.
- What is the 10Y average debt to equity ratio for DaVita Inc. (DVA)?
- The 10Y average debt to equity ratio for DVA stock is 15.10.
- What is the 15Y average debt to equity ratio for DaVita Inc. (DVA)?
- The 15Y average debt to equity ratio for DVA stock is 5.11.
- What is the 20Y average debt to equity ratio for DaVita Inc. (DVA)?
- The 20Y average debt to equity ratio for DVA stock is 2.84.
DaVita Inc. Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2024-12-31 | 99.63 |
| 2023-12-31 | 10.53 |
| 2022-12-31 | 16.60 |
| 2021-12-31 | 15.85 |
| 2020-12-31 | 8.09 |
| 2019-12-31 | 5.24 |
| 2018-12-31 | 2.73 |
| 2017-12-31 | 1.99 |
| 2016-12-31 | 1.96 |
| 2015-12-31 | 1.87 |
| 2014-12-31 | 1.64 |
| 2013-12-31 | 1.90 |
| 2012-12-31 | 2.27 |
| 2011-12-31 | 2.10 |
| 2010-12-31 | 2.19 |
| 2009-12-31 | 1.72 |
| 2008-12-31 | 1.89 |
| 2007-12-31 | 2.14 |
| 2006-12-31 | 3.01 |
| 2005-12-31 | 4.89 |
| 2004-12-31 | 2.63 |
| 2003-12-31 | 3.80 |
| 2002-12-31 | 18.78 |
| 2001-12-31 | 1.63 |
| 2000-12-31 | 2.79 |
| 1999-12-31 | 0.10 |
| 1998-12-31 | 2.59 |
| 1997-12-31 | 1.31 |
| 1996-12-31 | 0.45 |
Related Metrics
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Javier J. Rodriguez